Abstract: Liposomes have been used in technologies in biological, pharmaceutical, medical and nutritional applications because they can offer biocompatibility, biodegradability, reduced toxicity, and capacity for size and surface modifications. Traditionally, liposomes are prepared by multiple steps. However, multiple steps of preparation may cause a number of problems including low yield, high polydispersity, and poor morphology. Here, we synthesized liposomes containing magnetic iron oxide nanoparticle using one-pot, single step synthesis under ultra-sonication. We optimized the lipid compositions, sonication power, concentration of iron oxide nanoparticles, and antibody conjugation using Cu-free click chemistry. Furthermore, we incorporated doxorubicin inside magnetic liposomes for combined antibody targeting and magnetic guidance. Fluorescence imaging and quantification confirmed that antibody conjugated magnetic liposome showed high cell specific targeting that was enhanced by magnetic delivery.

Abstract: Compounds of formula III: and salts thereof are disclosed. Also disclosed are methods for preparing compounds of formula III, intermediates useful for preparing compounds of formula III and methods for preparing compounds and materials from compounds of formula III.

Abstract: Compounds of formula III: and salts thereof are disclosed. Also disclosed are methods for preparing compounds of formula III, intermediates useful for preparing compounds of formula III and methods for preparing compounds and materials from compounds of formula III.

Abstract: The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.

Abstract: The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.

Abstract: The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.

Abstract: The present invention relates to a novel crystalline form of lenalidomide having formula (I) and chemically known as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to a process for the preparation of said novel form and its use in pharmaceutical preparations for the treatment of autoimmune disease, inflammation, inflammatory disease and diseases such as cancer, in particular the management of multiple myeloma.